Kiora Pharmaceuticals(DE:7EY)
€0.380.00 (0.00%)
DE:7EY
Kiora Pharmaceuticals financials statements
€0.38
At close:0.00 (0.00%)
Kiora Pharmaceuticals (7EY) Ratios
0 Followers
Kiora Pharmaceuticals Ratios
DE:7EY's free cash flow for Q2 2026 was $-1.92M. For the 2026 fiscal year, DE:7EY's free cash flow was decreased by $-23.46K and operating cash flow was $-1.89M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.99 | 4.94 | 2.90 | 2.35 | 5.59 |
| Quick Ratio | 5.99 | 4.94 | 2.90 | 2.35 | 5.59 |
| Cash Ratio | 2.39 | 0.63 | 1.50 | 1.82 | 4.88 |
| Solvency Ratio | -1.33 | 0.34 | -1.64 | -1.86 | -2.47 |
| Operating Cash Flow Ratio | -2.74 | 1.42 | -5.85 | -3.19 | -6.63 |
| Short-Term Operating Cash Flow Coverage | -60.57 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 13.62M | $ 18.98M | $ -2.86M | $ 410.01K | $ 3.44M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.00 | 0.01 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.02 | 0.00 | 0.02 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.02 | 0.00 | 0.02 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.50 | 1.42 | 2.24 | 1.64 | 1.38 |
| Debt Service Coverage Ratio | -58.51 | 169.51 | -1118.48 | -1573.83 | -2002.41 |
| Interest Coverage Ratio | -473.91 | 210.31 | -1130.69 | -1431.51 | -2077.91 |
| Debt to Market Cap | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.09 | 0.02 | 0.22 | 0.16 | 0.90 |
| Net Debt to EBITDA | 0.69 | -0.66 | 0.19 | 0.43 | 0.55 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 35.51% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 35.63% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 28.19% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 35.37% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 22.47% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 22.47% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 89.42% | 63.51% | 100.73% | 99.17% | 98.62% |
| EBT Per EBIT | 128.10% | 125.49% | 98.70% | 111.27% | 98.09% |
| Return on Assets (ROA) | -44.67% | 9.85% | -91.26% | -72.72% | -68.41% |
| Return on Equity (ROE) | -67.19% | 13.95% | -204.82% | -119.08% | -94.46% |
| Return on Capital Employed (ROCE) | -45.87% | 14.80% | -104.21% | -79.90% | -76.86% |
| Return on Invested Capital (ROIC) | -40.69% | 9.39% | -103.81% | -78.70% | -75.32% |
| Return on Tangible Assets | -48.83% | 12.06% | -255.49% | -171.18% | -147.09% |
| Earnings Yield | -134.02% | 28.13% | -494.89% | -60.09% | -10.51% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 26.61 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 256.40 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.44 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 1.19 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -15604.68 | 13.71 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 13.71 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 15604.68 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 13.71 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.43 | 2.21 | -17.76 | -14.24 | -44.28 |
| Free Cash Flow Per Share | -2.45 | 2.21 | -17.76 | -14.24 | -44.54 |
| Dividend Paid and CapEx Coverage Ratio | -89.91 | 1368.14 | 0.00 | 0.00 | -167.16 |
| Capital Expenditure Coverage Ratio | -89.91 | 1368.14 | 0.00 | 0.00 | -167.16 |
| Operating Cash Flow Coverage Ratio | -27.05 | 149.71 | -89.41 | -98.58 | -50.98 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.53 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -124.58% | 66.93% | -377.95% | -46.13% | -8.19% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.75 | 3.55 | -0.20 | -1.66 | -9.52 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.80 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.50 | 0.50 | 0.41 | 1.98 | 8.99 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.80 | 1.49 | -0.26 | -2.17 | -12.20 |
| Price-to-Operating Cash Flow Ratio | -0.81 | 1.49 | -0.26 | -2.17 | -12.28 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | -0.03 | -0.01 | 0.02 | 2.68 |
| Enterprise Value Multiple | 0.02 | 1.59 | -0.01 | -1.23 | -8.87 |
| Enterprise Value | -243.68K | 9.04M | 180.84K | 16.75M | 123.42M |
| EV to EBITDA | 0.02 | 1.59 | -0.01 | -1.23 | -8.87 |
| EV to Sales | 0.00 | 0.57 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.02 | 1.06 | -0.02 | -1.61 | -11.49 |
| EV to Operating Cash Flow | 0.02 | 1.06 | -0.02 | -1.61 | -11.56 |
| Tangible Book Value Per Share | 3.43 | 4.92 | -5.03 | 0.91 | 15.81 |
| Shareholders’ Equity Per Share | 3.93 | 6.65 | 11.36 | 15.58 | 60.47 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.11 | 0.36 | -0.01 | 0.01 | 0.01 |
| Revenue Per Share | 0.00 | 4.13 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.64 | 0.93 | -23.26 | -18.55 | -57.12 |
| Tax Burden | 0.89 | 0.64 | 1.01 | 0.99 | 0.99 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.31 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.35 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.92 | 2.38 | 0.76 | 0.77 | 0.78 |
Currency in USD
